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Abstract
Background:  A previous study showed that a high percentage of children diagnosed with
Hyperkinetic Disorder (HKD) displayed a consistent pattern of motor function problems. The
purpose of this study was to investigate the effect of methylphenidate (MPH) on such motor
performance in children with HKD
Methods: 25 drug-naïve boys, aged 8–12 yr with a HKD-F90.0 diagnosis, were randomly assigned
into two groups within a double blind cross-over design, and tested with a motor assessment
instrument, during MPH and placebo conditions.
Results: The percentage of MFNU scores in the sample indicating 'severe motor problems' ranged
from 44–84%, typically over 60%. Highly significant improvements in motor performance were
observed with MPH compared to baseline ratings on all the 17 subtests of the MFNU 1–2 hr after
administration of MPH. There were no significant placebo effects. The motor improvement was
consistent with improvement of clinical symptoms.
Conclusion: The study confirmed our prior clinical observations showing that children with
ADHD typically demonstrate marked improvements of motor functions after a single dose of 10
mg MPH. The most pronounced positive MPH response was seen in subtests measuring either
neuromotor inhibition, or heightened muscular tone in the gross movement muscles involved in
maintaining the alignment and balance of the body. Introduction of MPH generally led to improved
balance and a generally more coordinated and controlled body movement.
Background
In a previous study we found that a high percentage of
children diagnosed with HKD showed functional prob-
lems associated with motor inhibition and stability prob-
lems[1]. Another study showed that children with ADHD,
who responded well to central stimulant medication on
attention and hyperactivity problems, showed more
motor problems than those who did not respond to this
medication[2].
The purpose of this study was to investigate the effects of
methylphenidate (MPH) on motor function in children
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with Hyperkinetic Disorder, HKD/F90.0 [3]. HKD is quite
similar to Attention Deficit Hyperactivity Disorder, com-
bined subtype, ADHD-C [4]. Motor function was assessed
using the Norwegian version of Motor Function Neuro-
logical Assessment battery, MFNU [5].
For further discussion of diagnostic considerations, see
Ellertsen and Johnsen [6]. In a previous paper [1] address-
ing motor problems in boys with ADHD-C/HKD, com-
pared to a control group without ADHD, it was found that
a high percentage of the ADHD group showed motor
problems. The percentage of 'severe problems' within the
17 sub tests of MFNU ranged from 44 – 84%, typically
over 60%. In all, 80–96% of the subjects showed prob-
lems when the scoring categories 'moderate'and 'severe'
problems' were combined. The rate of motor problems
reported in our study was markedly higher than the 30 –
50% typically reported in the literature [7-10].
Diagnosis of ADHD/HKD is made on the basis of behav-
ioural criteria alone. It involves a deficit in sustained
attention, impulse control and activity regulation across
situations like at home and at school for at least the past
6 months, starting before the age of 7 years [4,11]. There
is general agreement that ADHD is primarily neurobio-
logically based [12,13]. Neurophysiological studies have
shown that certain brain areas closely associated with
motor control seem to be involved in deficits in motor
inhibition, particularly the frontostriatal system, basal
ganglia and cerebellar vermis [14,15].
Methylphenidate (MPH) and d-amphetamine are consid-
ered the treatment of choice for ADHD, with a number of
studies indicating that approximately 80% of subjects
with ADHD show clinically significant benefits from such
treatment [16,17]. MPH is believed to activate self-regula-
tory control processes, thereby affecting what is believed
to be the core neurofunctional problems of the condition
and improving motor functions [18]. Thus, Lerer et al.
[19] showed that administration of MPH improved hand-
writing in children with what they called Minimal Brain
Dysfunction (MBD). This term has been abandoned, but
it is quite reasonable to assume that what is now termed
ADHD was a significant part of it [6]. In children with the
combined DSM IV diagnosis of ADHD and Developmen-
tal coordination disorder (DCD), Flapper et al. [20]
showed that medication with MPH for 5 weeks improved
handwriting and manual dexterity. Tucha and Lange [21-
23] concluded that children with ADHD, when with-
drawn from medication with MPH, showed poorer hand-
writing legibility and accuracy in comparison with the
control group. Improvement of qualitative aspects of
handwriting was found following treatment with stimu-
lant medication. Zeiner et al. [24] found that boys diag-
nosed with ADHD displayed a significantly lower counter
score on the Maze Coordination Test during MPH medi-
cation compared to placebo. The testing was performed
on the 15th or 16th day of each medication period. Rubia
et. al. [25] demonstrated that MPH improved motor tim-
ing in children with ADHD. MPH also improved speed of
inhibition and response execution processes [26]. O'Dris-
coll et al. [27], assessing eye movements in children with
ADHD, found that MPH improved motor planning and
response inhibition. Rubia et al[25] found that prolonged
administration, but not a single dose, of methylphenidate
reduced the variability of sensorimotor synchronization
and anticipation.
In the process of developing the MFNU, Stray [2] repeat-
edly observed that not only a prolonged treatment, but
also a single dose of central stimulants improved motor
performance and attention in individuals with ADHD.
This effect was usually observed 1/2 – 1 hour after medi-
cation, rapidly subsiding after 3–4 hr when a dosage of 10
mg MPH was delivered. It was also repeatedly observed
that when the same children were retested without medi-
cation, the motor problems had reoccurred. This pattern
was seen in children of both sexes, and over a wide age
range, including children who had been medicated for
years. The positive effect of MPH on motor performance
was observed not only on the MFNU, but in many areas
of daily living as well.
A pilot study, assessing 6 ADHD children with MFNU,
showed that all children had motor problems and that
administration of 10 mg MPH gave positive effects on
motor performance in all subjects after 90–120 min [2].
In order to pursue these findings, the present double-
blind MPH/placebo study was carried out, using the
MFNU as a test-retest procedure on 24 drug naïve boys
with the ADHD-C/HKD diagnosis.
Our hypothesis was that a single dose of MPH signifi-
cantly would improve MFNU motor function in children
with ADHD-C/HKD, compared to performance without
medication.
Method
Participants
A total of 25 out-patients boys, aged 8–12 years (mean age
10.2, SD 1.3) who were recently diagnosed at the Child
Psychiatry Department of a regional hospital were
recruited for the study. The diagnosis of ADHD was made
according to the ICD-10 criteria for Hyperkinetic disorder
(HKD) F90.0 [11]. They were all candidates for methyl-
phenidate evaluation at the hospital, and had no prior
experience with stimulant medication. The diagnosis was
set as a part of the ordinary assessment routines, based on
clinical interviews and consultations by a physician or a
clinical psychologist who incorporated information fromBehavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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the sources available. These included a report from a par-
ent or guardian, school reports for the last 12 months,
reports from other health professionals, and behavioural
observations during the assessment period. Parents and
teachers of the children completed standardized question-
naires (a Norwegian version of Barkley's DSM-IV rating
scale for ADHD)[28]. The WISC-R was administered in all
cases. Mean IQ was 97.6 (SD 15.9). Children were
excluded if they met ICD-10 criteria for Hyperkinetic dis-
order associated with conduct disorder (F 90.1), a depres-
sive or anxiety disorder, Asperger or Tourette syndrome or
known epilepsy. At a later point in time, and independent
of the present study, 23 of the children were assessed for
MPH effect on the core symptoms of ADHD at home and
at school. The remaining 2 children were, due to the par-
ent's choice, withdrawn from further MPH assessments at
the hospital. 21 of the 23 subjects responded positively to
MPH.
Motor assessment
The MFNU used in this study is thoroughly described in a
user manual and an accompanying DVD with videos of
MFNU-assessments of children without ADHD, and chil-
dren with ADHD tested without and with MPH medica-
tion [5]. The MFNU was developed over a 10 year period
in the 1990'ies in close collaboration with well-educated
and specialized personnel trained within the field of
ADHD, learning and conduct problems. Some of the sub-
tests were developed as part of the MFNU, and some are
modified versions of subtests from the Danish 'Funksjon-
snevrologisk Undersøgelse' (FNU)[29]. The subtests were
primarily chosen and designed to reveal problems with
motor inhibition and increased muscle tone, not motor
problems in general. A qualitatively based scoring system
is used. The test is performed in a highly "dynamic" and
interactional way with no limits concerning time and
number of attempts, in order to focus the attention of the
child [2,5].
Most of the subtests of the MFNU are performance tests
where the child is given an instruction to perform a certain
task (subtests 01–12). Subtests 13–16 are passive tasks
where the tester evaluates muscular resistance while
assessing hips and feet. Item 17 'Synkinesis', is an evalua-
tion of the presence of synkinetic movements during the
examination. Subtest 18, 'Palpation', was omitted from
the study, as it can not be scored on the basis of video
recordings. Table 1 presents a brief description of the sub-
tests used.
The MFNU is scored on a sheet applying a ranked 3-cate-
gory format (0–1–2). The subtests are scored according to
Table 1: The subtests of MFNU used in the study
Name of subtests and video examples Description
01. Dynamic balance-2 legs Three sideway jumps within marked squares, back and forth. The entire process is repeated three times 
without stopping.
02. Dynamic balance-1 leg Three sideway jumps on one leg within marked squares, back and forth. The entire process is repeated 
three times without stopping. Both legs are tested.
03. Diadochokinesis-right
04. Diadochokinesis-left
Pronation-supination of one hand, the elbow flexed 90 degrees. The hand is held as an "extension" of the 
lower arm. The exercise is performed for approximately 15–20 seconds.
05. Reciprocal coordination Alternate clenching of one fist, and stretching of the other in a rhythmic manner, for about 15 seconds. 
Fingers should be nearly completely extended after the hand has been clenched. Elbows at a 90 degree 
angle, palms facing upwards.
06. Thumb movement The tip of the other fingers are successively touched with the palmar surface of the tip of the thumb. After 
each opposition the child extends and abducts the thumb. Both hands are tested for approximately 20 
seconds.
07. Throw ball The tester plays ball with the child. A fearly large ball is used. The child has to throw with dominant arm in 
an upwards position. Shoulder movement is scored.
08. Catch ball The tester plays ball with the child. A tennis ball is used. The child has to catch the ball with one hand, 
fingers flexed, without touching the body.
09. Walking Walking with toes alternately pointing outwards ("Chaplin") and inwards, followed by walking on the outer 
foot rend (Fog's test) and inner foot rend.
10. Lifting arm Lies prone, arms in a 45 degree angle from midline, lifting one arm with the palm of the hand facing the 
floor.
11. Lifting leg Lies prone, spina iliaca anterior is touching the floor while lifting one stretched leg at a time.
12. "Flying" Lies prone, the arm in a 45 degree angle from midline, lifting head, arms and legs.
13. Passive abduction-right hip
14. Passive abduction- left hip
Lies supine. Tester holds the child's knee and hip in a flexed position. The tester stretches and flexes the 
leg to elicit a relaxation of the hip muscles, and abducts the leg. The sides are evaluated separately.
15. Passive movement-right foot
16. Passive movement-left foot
Lies supine. Tester examines passive movement with dorsal flexion and eversion/plantar flexion of the right 
and the left foot.
17. Synkinesis 'Synkinesis' is not a separate test, but an item for the evaluation of synkinetic movements registered in one 
or more subtests. When observed, the tester tries to correct it. The remaining synkinesis after correction 
is scored.Behavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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the criteria presented in Table 2. More detailed criteria for
each subtest are given in the MFNU manual and visual-
ized in the accompanying DVD [5]. Inter-tester reliability
analyses have shown high to very high rater agreement on
all subtests (Cohen's Kappa ranging from .67 to 1.00) [2].
A scoring system based on observed changes in perform-
ance is used when comparing test-retest performances. A
change score ranging form -3 to +3 is applied, where a
score of '0' means no change. A score of '+1' or '-1' means
that observable change in performance is registered, but
not qualifying for a score across a category. This scoring
system permits a more subtle evaluation of change in per-
formance than if the 3-category system had been used for
this purpose. Intraclass correlation between two trained
raters ranged from .79 to .99 (Stray et al. article in prepa-
ration). See Table 3 for a detailed description of the scor-
ing system. See also the MFNU manual for specific scoring
criteria, and the accompanying DVD for video illustra-
tions of the dual display comparison involved in the test-
retest rating procedure.
Design
A double-blind, placebo controlled, crossover design was
applied, using study capsules with a single dose of 10 mg
immediately released methylphenidate (MPH) or placebo
(approved by the Norwegian Medicines Control Author-
ity). The children were randomly assigned into two
groups by a simple randomization procedure, resulting in
15 subjects allocated to Group A (receiving placebo on
day 1 and methylphenidate (MPH) on day 2) and 10 sub-
jects to Group B (receiving MPH on day 1 and placebo on
day 2). The researchers, the participants and the rater of
the videos were blinded with the regard to group assign-
ment. The "key" to the treatment assignments was una-
vailable throughout the study period. One patient
belonging to group B dropped out after the first day,
reducing this group to 9 subjects.
Procedures
The children were tested individually with the MFNU two
times a day on two different days, with an interval of 2 to
24 days (median 5 days). Study capsules were adminis-
tered according to the design displayed in Table 4. The 10
mg of MPH, or placebo, was administered immediately
after the baseline trial each day (Trial 1 and 3 respectively)
(the result of the two trials without medication were pre-
sented in a previous study, where the ADHD group was
compared to a control- group [1]). The retest was done 90
min after administration of MPH/placebo both days.
The children were assessed individually at the hospital
with their parents being present. All sessions were video-
taped. Prior to the test sessions all subjects went through
a consultation with a physician (the fourth author), and a
preliminary MFNU assessment with the physical therapist
(the first author). The preliminary trial was given in order
to avoid possible negative test results due to distraction or
to emotional reaction to an unfamiliar situation.
The rating of each child was performed by a trained phys-
iotherapist at a later point in time, based on the video-
tapes from each session. The rater had no prior knowledge
to any of the children. The sessions were displayed in
blinded order on two parallel screens showing the base-
line trial (Trial 1 or 3) on the left screen and the compared
MPH/placebo (Trial 2 or 4) on the right. The sound was
turned off during the rating in order to ensure that verbal
comments from the participants would not influence the
rater.
The scoring sheet consisted of one row and three scoring
columns for each subtest, representing the scoring catego-
ries 0, 1 and 2. The baseline scores were evaluated and
marked first, using a pencil with a specific colour. The
scores of the comparison trials were subsequently marked
within the same set of columns, with different colours for
each trial.
Each subtest was given a Category score from 0–2 on each
trial. In addition a separate Change score was set for each
of the successive trial according to the rules described in
Table 3. A 'Total score', which is the sum of the Category
scores of 17 subtests for each subject, was computed for
Table 2: Scoring criteria for the 17 subtests of MFNU
Score: Criteria
subtests 01–12 subtests 13–16 subtest 17
0 'No problems' The task is performed with no 
problems and little effort
Normal resistance against the 
movement is registered
Only sporadic synkinetic movements are 
registered
1 'Moderate problems' The task is performed according to 
instruction, but with lot of attention 
and effort, or quality of performance 
is below what is expected for age
Resistance against the movement is 
registered
Moderate synkinetic movements are 
registered in one or more subtest
2 'Severe problems' The child can not perform the task 
according to the instruction
Severe resistance against the 
movement is registered
Pronounced synkinetic movements are 
registered in one or more subtestBehavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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each of the four trials. The Total score ranges from 0 to 34.
In a previous study, a very high internal consistency
within the total set of sub-tests was found (Cronbach's
Alpha = 0.98) [1]. This variable is assumed to be continu-
ous and was used to illustrate the severity of the motor
problems.
Data analyses
The statistical analyses were carried out using the SPSS ver-
sion 15.0. Distributions of the scoring categories (0–1–2)
and of the change scores for each subtest, and for the Total
score were obtained from the registered baseline, placebo
and MPH data. Effects of MPH were analysed using the
Wilcoxon Signed-rank test for related samples to compare
the performances during baseline, placebo and MPH trials
on each of the 17 subtests and on the Total score. Mann
Whitney U-tests were used to compare the two groups.
Non-parametric tests were applied because the data were
not normally distributed, and because the measurement
level was ordinal for the subtests. Cohen's d-analysis was
used for calculation of the effect size of the Total score.
Approvals
The study was approved by the Norwegian Data Inspector-
ate, The Regional Committee for Medical Research Ethics,
Norwegian Medicines Agency, the research committee
and the director of medicine at the Department of child
and adolescent mental health, Sørlandet Hospital, Kris-
tiansand, Norway,
Results
When comparing the placebo performance of the A and B
groups on the individual subtests no significant differ-
ences were found for 16 of the 17 subtests (Mann-Whit-
ney U-test). A tendency towards a weaker placebo
performance on some of the subtest was registered in the
group receiving placebo on the second day (fourth ses-
sion). The differences were non-significant for the subtests
except 'Thumb movement' (p = .04). There were no signif-
icant differences between Group A and Group B on Total
score when comparing the baseline, MPH or placebo ses-
sions. This indicated that the A and B-group could be
treated as one group (N = 24) in further analyses.
Table 5 shows the relative distribution of scores in the cat-
egories 0–2 for the whole group on each subtest on the
baseline, MPH and placebo condition. The most pro-
nounced improvements with MPH compared to baseline
were observed on the passive movement tests (13–16),
the extension subtests (10–12) and 'Throw ball' (07). The
movement of the hips was markedly better for a majority
of the children (83.3% score 2 on baseline 1 and baseline
2 and 12.5% on the MPH trial for the right hip and a
change from 79.2% to 8.3% for the left). On the MPH trial
for the subtest 'Lifting arms' (10), many of the children
were able to lift one arm at a time with the palm of the
hand facing the floor, maintaining the angle from mid-
line. Only 25% compared to 58.3% on the baseline trials
showed severe problems on this item. When medicated
with MPH, only 16.7% of the children showed severe
problems on the subtest 'Lifting legs' (11), and 33.3% of
the children were able to lift one stretched leg at a time
keeping the spina iliaca on the floor, compared to 4.2%
on baseline 2 and the placebo trial. When performing the
subtest 'Throw ball' (07) with MPH, only 16.7% of the
children, as compared to 58.3% on the baseline 1 and pla-
cebo trial, showed severe problems when throwing with
the arm in an upward position. Passive movement of the
right foot was improved by MPH (70.8% with severe
problems on baseline 1, 79.9% on baseline 2 and only
4.2% on the MPH trial).
The Wilcoxon test showed significant improvements on
all subtests when comparing baseline 1 to the MPH trial
(see Table 6). No significant differences were found
between the baseline 1 and the placebo trial except for
subtest 10 'Lifting arm' which showed more problems on
the placebo trial (p < .05).
Table 3: The change scores used in MFNU in test-retest 
procedures
Change score
Neg. change across two categories -3
Neg. change across one category -2
Neg. change within same category -1
No change 0
Pos. change within same category 1
Pos. change across one category 2
Pos. change across two categories 3
Table 4: The cross-over design of the experiment
Day 1 Day 2
Trial 1 Trial 2 Trial 3 Trial 4
Group A (n = 15) No medication Placebo No medication 10 mg MPH
Group B (n = 10)* No medication 10 mg MPH No medication Placebo
* 1 of the subject of Group B did not attend Day 2, reducing the N to 9.Behavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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Table 5: The percent distribution of the 3 scoring categories on baseline 1, baseline 2 (trial 3), MPH and placebo trial (N = 24)
Score 0
%
Score 1
%
Score 2
%
Subtests of MFNU Bas.1 Bas. 2 MPH Plac. Bas.1 Bas. 2 MPH Plac Bas. 1 Bas. 2 MPH Plac.
01. Dynamic balance, 2 legs 12.5 12.5 20.8 12.5 33.3 33.3 41.7 29.2 54.2 54.2 37.5 58.3
02. Dynamic balance, 1 leg 4.2 0.0 16.7 0.0 25.0 29.2 37.5 25.0 70.8 70.8 45.8 75.0
03. Diadochokinesis, right 8.3 4.2 12.5 4.2 25.0 25.0 54.2 25.0 66.7 70.8 33.3 70.8
04. Diadochokinesis, left 4.2 0.0 8.3 0.0 29.2 9.2 45.8 29.2 66.7 70.8 45.8 70.8
05. Reciprocal coordination 8.3 0.0 20.8 0.0 29.2 33.3 54.2 33.3 62.5 66.7 25.0 66.7
06. Thumb movement 12.5 12.5 29.2 12.5 20.8 20.8 45.8 25.0 66.7 66.7 25.0 62.5
07. Throw ball 8.3 8.3 25.0 4.2 33.3 37.5 58.3 37.5 58.3 54.2 16.7 58.3
08. Catch ball 16.7 12.5 20.8 8.3 33.3 37.5 54.2 41.7 50.0 50.0 25.0 50.0
09. Walking 20.8 16.7 20.8 8.3 12.5 12.5 41.7 12.5 70.8 70.8 37.5 70.8
10. Lifting arm 8.3 0.0 33.3 0.0 33.3 41.7 41.7 33.3 58.3 58.3 25.0 66.7
11. Lifting leg 12.5 4.2 33.3 4.2 41.7 45.8 50.0 45.8 45.8 50.0 16.7 59.0
12. "Flying" 8.3 0.0 41.7 0.0 29.2 37.5 37.5 37.5 62.5 62.5 20.8 62.5
13. Passive abduct. right hip 12.5 4.2 62.5 8.3 4.2 12.5 25.0 8.3 83.3 83.3 12.5 83.3
14. Passive abduct. left hip 8.3 12.5 75.0 4.2 12.5 8.3 16.7 16.7 79.2 79.2 8.3 79.2
15. Passive move. right foot 8.3 4.2 37.5 4.2 20.8 16.7 58.3 16.7 70.8 79.2 4.2 79.2
16. Passive move. left foot 16.7 8.3 62.5 4.2 20.8 33.3 33.3 33.3 62.5 58.3 4.2 62.5
17. Synkinesis 12.5 4.2 12.5 4.2 20.8 29.2 62.5 29.2 66.7 66.7 25.0 66.7
Score 0:'No problems'
Score 1:''Moderate problems'
Score 2:'Severe problems'
Table 6: Results of significance tests (Wilcoxon signed ranks test) when comparing MPH/placebo scores against baseline 1(category 
scores).
MPH trial – baseline1 placebo trial – baseline1
Subtets of MFNU p-value z p-value z
01. Dynamic balance, 2 legs .014 -2.449a .317 -1.000b
02. Dynamic balance, 1 leg .007 -2.714a .317 -1.000b
03. Diadochokinesis, right .003 -3.000a .157 -1.414b
04. Diadochokinesis, left .014 -2.449a .157 -1.414b
05. Reciprocal coordination .003 -2.972a .083 -1.732b
06. Thumb movement .004 -2.889a .317 -1.000b
07. Throw ball .000 -3.500a .317 -1.000b
08. Catch ball .008 -2.646a .317 -1.000b
09. Walking .005 -2.828a .317 -1.000b
10. Lifting arm .000 -3.500a .046 -2.000b
11. Lifting leg .001 -3.207a .083 -1.732b
12. "Flying" .000 -3.626a .157 -1.414b
13. Passive abduct. right hip .000 -3.852a .317 -1.000b
14. Passive abduct. left hip .000 -4.072a .317 -1.000b
15. Passive move. right foot .000 -3.906a .083 -1.732b
16. Passive move. left foot .000 -3.729a .180 -1.342b
17. Synkinesis .002 -3.126a .157 -1.414b
a. Based on positive ranks
b. Based on negative ranksBehavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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Fig. 1 presents the distribution of the 'Total Problem
Score' (N = 24) grouped into 5 categories under the 4 dif-
ferent testing conditions. With MPH only 24% of the sub-
jects showed marked or severe problems (Total score 20 or
higher), as compared to 76% on the baseline trial and
84% on the placebo trial. The figure also clearly reveals
that placebo had no positive effect on performance.
Fig. 2 illustrates the Total score differences between base-
line 1 and MPH and between baseline 1 and placebo per-
formances for each subject. Subject no 19 showed no
effect of MPH.
A marked negative responses to placebo compared to
baseline 1 was registered in 3 subjects (Fig. 3). Only minor
changes were registered from baseline 1 to placebo for the
rest of the sample indicating that the placebo condition
yielded no positive effect on motor performance.
When the 7 category 'Change score' system was applied,
the passive movement subtests (13–16) showed the high-
est percentage of positive change across two categories
(from 'severe' to 'no problems') from baseline to MPH
trial (See Table 7). On the dynamic balance subtests (01–
02) 'Diadochokinesis, left', (04) 'Reciprocal coordination'
(05) and 'Walking' (09) a relatively high percentage of the
subjects were scored in the +1 category ('Positive change
within the same category').
During a later assessment performed by the hospital 21
out of the 23 boys showed a positive MPH response at
home and at school on the core symptoms of ADHD. One
of the two non-responders had a Total score of 18 on the
baseline and placebo trials and of 15 on the MPH trial.
The other subject obtained a Total score of 23 on baseline
and placebo trials, and 16 on the MPH trial (improve-
The Total score for the baseline, placebo and MPH trials (N = 25) Figure 1
The Total score for the baseline, placebo and MPH trials (N = 25). shows the distribution of the Total score for the 
baseline, placebo and MPH trials (N = 25). The Total score is categorized into 5 categories, ranging from 0 to 34, where a 
score of 0 means 'no problems' on any subtest, and 34 means a score of 2 ('severe problems') on all 17 subtests.Behavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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ment on the 'passive movement tests', 'Lift arm' and 'Syn-
kinesis').
A Cohen's d-analysis of effect size was performed applying
the Total score of the MPH and the baseline 1 trials to
establish the statistical power of the effects shown in the
study. A Cohen's d of 1,27 was found, which according to
Cohen [30] is a substantial effect size.
Discussion
The results support our hypothesis that MPH would sig-
nificantly improve motor function in children with
ADHD-C/HKD compared to performance without medi-
cation. Improved performance with MPH was demon-
strated on all the 17 subtests of the MFNU. Performance
under placebo conditions was not significantly different
from performance during the baseline trials ruling out
that the improvements on MPH might be explained by a
placebo effect.
While improved performance with MPH was registered on
all the subtests of the MFNU, the greatest improvements
were observed on subtests constructed to measure
increased muscle tone in the "movement muscles" (for
instance m. Latissimus dorsi and m. Psoas major) (sub-
tests 07, 10,12–14) (see Additional files 1 and 2 for exam-
ple of a positive change from category score 2 to score 1
on subtest 14). A reduced muscle tone and better adjust-
ment of the shoulder and hip muscles may be an explana-
tion. The improvement was also pronounced on the
subtests 'Passive movement of the left and right foot '(15–
16), revealing problems in the calf muscles. These muscles
are important in maintaining body alignment [31]. A high
degree of improvement was also observed on the subtest
'Thumb movement', measuring neuromotor inhibition
problems see Additional files 3 and 4 for example of a
positive change from category score 2 to score 0).
It has been shown in previous studies that MPH signifi-
cantly reduces activity level in children with ADHD and
enhances sustained attention, as well as the speed and
organization of motor response processes and motor
inhibitory control [32]. Administration of MPH has also
been shown to improve handwriting in children with
ADHD [21,22]. A restricted movement of the shoulder,
elbow and thumb may negatively affect the quality of
handwriting. Our results indicate that a single dose of
MPH significantly improved the movement of the thumb,
Total score for the baseline 1 and MPH trials for 25 subjects Figure 2
Total score for the baseline 1 and MPH trials for 25 subjects. shows the Total scores on the baseline 1 and the MPH 
trials for each subject.Behavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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the elbow (pronation-supination) and the shoulder (the
subtests 'Throw ball' and 'Lifting arm') in boys with
ADHD-C/HKD. It is quite possible that these improve-
ments may account for the positive effect of MPH on
handwriting shown by Tucha and Lange [21,22]. Our
study also showed improved movement of the hips and
feet (subtest 13–16) with MPH. Restricted hip and feet
movements may negatively affect gait and jumping.
Most of the above mentioned subtests were developed to
demonstrate specific motor problems in ADHD. For the
rest of the subtests (1–4, 8, 9 and 17), which are mainly
adaptations of other tests of motor function, the improve-
ment with MPH was not so pronounced, compared to the
first mentioned group of subtests. A close examination of
the scoring patterns on the subtests 1–4, 8, 9 and 17 using
the Change score system, revealed that the main improve-
ment observed in these tests was rated within the original
baseline category (+1 scores), with relatively fewer exam-
ples of change across categories (+2 and +3).
Our present study indicates a close correspondence
between the subtest with the highest discriminative
power, as shown by Stray et al[1], and the subtests show-
ing consistently strong improvement with MPH. This
finding supports our assumption that these subtests tap
motor problems that are strongly related to the core neu-
rofunctional problems of ADHD. The possible neuro-
physiological connection between motor problems
demonstrated by the MFNU and the core problems of
ADHD is discussed at length in the MFNU manual [5],
and by Stray [2], and in Stray et al. [1].
What we wanted to examine in this study was the possible
power of the MFNU as a predictor of MPH response in
children with ADHD. The results indicate that the chil-
dren with high scores on the subtests measuring problems
in motor inhibition or heightened tensions in the move-
ment- and stabilizing muscles consistently show a clear
improvement rate with MPH. In our study, with a well-
defined and selected HKD F-90.0 sample, 21 out of 23
subjects (91%) showed a positive field response to MPH.
This result is very promising when positive prediction is
considered. However, the study can not tell us whether
children diagnosed with ADHD combined and with a low
Total score on the MFNU will tend to show a negative clin-
ical MPH response. A prior study by Stray [2], using a
selection of the MFNU subtests, suggested such a relation-
The Total scores for each subject on the baseline 1 (N = 25) and placebo trials (N = 24) Figure 3
The Total scores for each subject on the baseline 1 (N = 25) and placebo trials (N = 24). shows the Total score on 
the baseline 1 and the placebo trials for each subject. Subject nr 5 did not attend the placebo trial.Behavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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ship. This study retrospectively compared the clinical
MPH results of 73 ADHD children with results of a selec-
tion of MFNU subtests obtained before diagnosis and
clinical MPH evaluation of the core problems of ADHD.
The results showed significantly more motor problems in
positive clinical responders to MPH than in the non-
responder group, indicating that a low score on the MFNU
reduced the chance of positive MPH responses on atten-
tion/hyperactivity. However, more controlled studies with
an ADHD sample with a higher representation of normal
motor performers are needed to clarify this issue.
Limitations
The fact that the results of the present study yield very
strong support to our hypotheses makes a careful scrutiny
of possible weaknesses in the design necessary. A possible
weakness in the MFNU scoring system might be linked to
the reliance on subjective judgements involved in decid-
ing on the basic category scores (0–2). However, well
defined scoring criteria [5], together with the documented
high inter-rater reliability of the basic 3-category-scoring
system makes it improbable that rater bias or other factors
associated with subjective rating contributed to the results
in any significant way. The perhaps most problematic part
of the design is associated with the use of one scoring
sheet for all observations. With repeated sessions the
raters had access to prior scoring. It is quite possible that
the results would have been less clear if the raters had
been blinded to prior ratings by the use of separate scoring
sheets for each repeated session. However, the rating pro-
cedure, which is the standard way of evaluating test-retest
performance with the MFNU [5], was chosen to make an
evaluation of changes in performance both across catego-
ries and within the same category possible. As illustrated
by Table 7 this ability of the scoring system to detect finer
differences in individual test-retest performance is partic-
ularly evident in the subtests which involve complex
movements like dynamic balance and synkinesis. The use
of a blinded 3-category rating of each trial would probably
have missed out many of these clinically important differ-
ences. The fact that our design applying the dual screen
setup and single sheet scoring has proven reliable in inter-
tester-reliability analyses (ICC = .79 – .99), also makes it
improbable that rater bias effects influenced the results of
our study in any important way.
The subjects included in this study were carefully selected
to identify a well-defined ADHD-C/HKD F 90.0 sample,
excluding subjects with conduct disorder, depressive or
anxiety disorder, Asperger or Tourette syndrome or
known epilepsy or the ADHD-I or H type of clinical prob-
lems. This implies that our conclusions cannot be gener-
alized to the broader ADHD population as defined by the
DSM-IV. Other clinical conditions where co-morbid
ADHD symptoms are present may show a different pic-
ture with regard to MPH response on motor problems.
Since the sample consisted of boys only, and in a limited
age range, reservations should also be taken when gener-
alizing our conclusions to girls with ADHD and to older
individuals.
Table 7: Distribution of Change scores on 17 subtests of MFNU when performance on baseline and MPH trials are compared (N = 25)
Negative change 
one category
Negative change 
within same 
category
No 
change
Positive change 
within same 
category
Positive change 
one category
Positive change 
two categories
Subtests of MFNU Score = -2 Score = -1 Score = 0 Score = +1 Score = +2 Score = +3
01. Dynamic balance, 2 legs 0 1 6 12 6 0
02. Dynamic balance, 1 leg 0 0 6 11 7 1
03. Diadochokinesis, right 0 0 7 10 8 0
04. Diadochokinesis, left 0 0 6 11 8 0
05. Reciprocal coordination 0 0 5 12 6 2
06. Thumb movement 0 0 5 8 8 4
07. Throw ball 0 0 6 8 11 0
08. Catch ball 0 0 6 12 7 0
09. Walking 0 1 5 9 10 0
10. Lifting arm 0 0 3 10 11 1
11. Lifting leg 0 0 3 10 11 1
12. "Flying" 0 0 3 6 13 3
13. Passive abduct. right hip 0 0 5 1 7 12
14. Passive abduct. left hip 0 0 4 1 6 14
15. Passive move. right foot 0 0 4 1 14 6
16. Passive move. left foot 0 0 6 1 11 7
17. Synkinesis 1 1 5 8 10 0Behavioral and Brain Functions 2009, 5:21 http://www.behavioralandbrainfunctions.com/content/5/1/21
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Conclusion
Our study demonstrated that administration of a single
dose of MPH in boys diagnosed as ADHD-C/HKD F 90.0
yields a significant improvement in motor problems, as
measured with the MFNU, and that this effect disappears
when the MPH is metabolised. The improvements are
seen in all areas assessed within the MFNU, including
direct and indirect symptoms of motor disinhibition, bal-
ance, synkinesis and muscle tone of compensating mus-
cles. The results support our earlier clinical observations
and our suggestions that motor problems in ADHD may
be a more integrated part of the core problems of the dys-
function than previously assumed. While a high total
score on the MFNU predicts a positive MPH response on
motor performance, further research is needed to establish
the strength of the MFNU as a predictor of MPH response
on the behavioural symptoms. It would also be of great
interest to study ADHD subjects with little or no motor
problems, both to decide if their core problems are differ-
ent from ADHD subjects scoring high on MFNU, and if
MPH works in a different or less effective way in these
children. Further controlled studies of motor problems in
ADHD in connection with MPH, may also contribute to a
clarification of many of the unresolved theoretical issues
associated with the neurobiological basis of ADHD.
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Additional file 1
Passive abduction – left hip ADHD no medication. This video clip 
shows the MFNU subtest 'Passive abduction – left hip' performed on a 
child diagnosed with ADHD-C/HKD. The child had been medicated with 
MPH for several years. Medication was stopped one day before the video 
tape was made. The video clip is selected from the DVD accompanying the 
MFNU manual [5].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1744-
9081-5-21-S1.wmv]
Additional file 2
Passive abduction – left hip ADHD with MPH. This video clip shows 
the MFNU subtest 'Passive abduction – left hip' performed on the same 
child as presented in the previous clip. The video tape was made 1 1/2 hr 
after medication with 10 mg MPH on the same day. The video clip is 
selected from the DVD accompanying the MFNU manual [5].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1744-
9081-5-21-S2.wmv]
Additional file 3
Thumb movement ADHD no medication. This video clip shows the 
MFNU subtest 'Thumb movement' performed by the same child as pre-
sented in the previous clips. Medication was stopped one day before the 
video tape was made. The video clip is selected from the DVD accompa-
nying the MFNU manual [5].
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9081-5-21-S3.wmv]
Additional file 4
Thumb movement ADHD with MPH. This video clip shows the MFNU 
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10 mg MPH on the same day. The video clip is selected from the DVD 
accompanying the MFNU manual [5].
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